Stealth BioTherapeutics Completes Target Enrollment in Global Phase 3 NuPOWER Trial in Patients with Primary Mitochondrial Myopathy

Stealth BioTherapeutics Inc. today announced its achievement of target enrollment in the NuPOWER (SPIMD-301) study in patients with primary mitochondrial myopathy (PMM).